FYB 207
Alternative Names: ACE2-IgG1-Fc; FYB-207Latest Information Update: 28 Feb 2025
Price :
$50 *
At a glance
- Originator Formycon
- Class Antivirals; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in Germany
- 03 Nov 2022 Pharmacodynamics data from a preclinical trial in COVID-2019 infections released by Formycon
- 03 Nov 2022 Formycon plans a clinical trial for COVID-2019 infections in 2023